Caris Life Sciences(NASDAQ) CAI

Caris Life Sciences helps doctors treat cancer with biology data. It uses artificial intelligence to study tumor samples and blood. These tests help find the best medicine for each patient.

A Platform for Precision Medicine

• Molecular Profiling Services: Comprehensive gene sequencing tests for tissue and blood samples used to guide cancer therapy; accounted for 96% of revenue in the three months ended June 30, 2026.
• Digital Prognostic Solutions: Machine learning tools that use medical imaging and clinical data to assess how a disease may progress; prognostic refers to predicting the course of a medical condition.
• Pharma Services: Research and data insights provided to drug companies to support therapeutic development; accounted for 4% of revenue in the three months ended June 30, 2026.

Recent Strategic Milestones

• Launched Caris Detect, Caris ChromoSeq, and Caris MI Clarity during the second quarter of 2026.
• Released the MI Cancer Seek solution in Jan. 2025 following authorization from the Food and Drug Administration in late 2024.
• Commenced the broad commercial rollout of the Caris Assure platform for therapy selection in the first quarter of 2024.
• Maintains partnerships with biopharmaceutical firms including Moderna, AbbVie, and Genentech to increase the success rates of their drug pipelines.
• Secured a $400 million senior credit facility in April 2026 to refinance existing debt and fund operations.

Scaling Data and Intelligence

Caris performs both whole exome sequencing, which maps protein-coding DNA, and whole transcriptome sequencing, which measures gene activity, on every patient sample. This consistent approach has created a clinico-genomic data set with results from more than 1,130,000 cases as of June 30, 2026.

Key Performance Metrics

• Total revenue was $263.7 million for the three months ended June 30, 2026, up 45.4% year over year.
• Clinical case volume rose to 59,200 in the quarter ended June 30, 2026, compared to 50,000 in the prior year.
• Net loss narrowed to $637,000 in the three-month period ended June 30, 2026, from $71.8 million in 2025.
• Cash, cash equivalents, and marketable securities totaled $794.9 million as of June 30, 2026.

Bottom Line

Caris has evolved from a laboratory service into a biology technology firm driven by artificial intelligence. By combining massive genomic data sets with diagnostic tools, it has built a platform for precision cancer care.